| Identification | Back Directory | [Name]
JAK-IN-5 | [CAS]
2096999-92-5 | [Synonyms]
JAK-IN-5
Phenol, 5-ethyl-2-fluoro-4-[3-[4,5,6,7-tetrahydro-5-(1-methyl-4-piperidinyl)-3H-imidazo[4,5-c]pyridin-2-yl]-1H-indazol-6-yl]- | [Molecular Formula]
C27H31FN6O | [MDL Number]
MFCD31657397 | [MOL File]
2096999-92-5.mol | [Molecular Weight]
474.57 |
| Chemical Properties | Back Directory | [Boiling point ]
734.5±60.0 °C(Predicted) | [density ]
1.311±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
8.54±0.25(Predicted) |
| Hazard Information | Back Directory | [Description]
JAK inhibitor 1 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. | [Uses]
JAK-IN-5 is an inhibitor of JAK extracted from patent US20170121327A1, compound example 283. | [in vivo]
JAK-IN-5 (compound 1) (oral aspirate, 0.5 mg/mL, 50 μL ) inhibits STAT6 phosphorylation by 60% in IL-13-induced in lung tissue in a mouse model of pSTAT6 induction[2].
JAK-IN-5 (compound 1) (oral aspirate, 0.1-1.0 mg/mL, 50 μL) inhibits 88% of BALF eosinophils in male C57 mice model of Alternaria alternata-induced eosinophilic inflammation of the lung[2].
| [References]
[1]. Paul R. Fatheree, et al. JAK Kinase Inhibitor Compounds for Treatment of Respiratory Disease. US20170121327A1 |
|
|